- Home
- ACRS vs LVO Comparison
ACRS vs LVO Comparison
Compare ACRS & LVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- LVO
- Stock Information
- Founded
- ACRS 2012
- LVO 2009
- Country
- ACRS United States
- LVO United States
- Employees
- ACRS N/A
- LVO N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- LVO Restaurants
- Sector
- ACRS Health Care
- LVO Consumer Discretionary
- Exchange
- ACRS Nasdaq
- LVO Nasdaq
- Market Cap
- ACRS 132.0M
- LVO 117.0M
- IPO Year
- ACRS 2015
- LVO N/A
- Fundamental
- Price
- ACRS $2.24
- LVO $0.84
- Analyst Decision
- ACRS Strong Buy
- LVO Strong Buy
- Analyst Count
- ACRS 5
- LVO 2
- Target Price
- ACRS $11.00
- LVO $2.75
- AVG Volume (30 Days)
- ACRS 656.6K
- LVO 858.3K
- Earning Date
- ACRS 03-04-2025
- LVO 02-13-2025
- Dividend Yield
- ACRS N/A
- LVO N/A
- EPS Growth
- ACRS N/A
- LVO N/A
- EPS
- ACRS N/A
- LVO N/A
- Revenue
- ACRS $27,079,000.00
- LVO $126,016,000.00
- Revenue This Year
- ACRS N/A
- LVO $5.30
- Revenue Next Year
- ACRS N/A
- LVO N/A
- P/E Ratio
- ACRS N/A
- LVO N/A
- Revenue Growth
- ACRS 26.35
- LVO 11.43
- 52 Week Low
- ACRS $0.95
- LVO $0.56
- 52 Week High
- ACRS $5.17
- LVO $2.15
- Technical
- Relative Strength Index (RSI)
- ACRS 39.59
- LVO 34.54
- Support Level
- ACRS $2.11
- LVO $0.82
- Resistance Level
- ACRS $2.42
- LVO $0.95
- Average True Range (ATR)
- ACRS 0.15
- LVO 0.13
- MACD
- ACRS 0.00
- LVO -0.04
- Stochastic Oscillator
- ACRS 26.53
- LVO 3.13
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
About LVO LiveOne Inc.
LiveOne Inc, formerly LiveXLive Media Inc is a premium internet network devoted to live music and music-related video content. The company has been building an online destination for music fans to enjoy live performances from music venues and music festivals around the world, such as Rock in Rio, Outside Lands Music and Arts Festival, and Hangout Music Festival, as well as original content, artist exclusives, and industry interviews. The Company operates mainly through three segments, PodcastOne, Slacker, and Media Group, with a majority of its revenue derived from the Slacker segment.